Neuland Laboratories Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Neuland Laboratories (NSE: NEULANDLAB) is preparing to announce its Q4 FY26 financial results for the quarter ending March 31, 2026. With the stock trading at Rs 11,200 and a 52-week range of Rs 9,800–Rs 18,500, the Q4 FY26 results will be a pivotal event for investors tracking the Pharma sector. This article covers the confirmed results date, Q4 FY26 analyst earnings estimates, five key performance drivers, five risks to monitor, and analyst ratings with price targets ahead of the results announcement.

Q4 FY26 (January to March 2026) is the final quarter of the financial year, carrying special importance as it determines the full-year FY26 performance baseline, sets FY27 estimate benchmarks, and typically triggers final dividend announcements. For Pharma companies, Q4 is historically a seasonally important quarter influenced by year-end government spending, project completions, and management guidance for the year ahead.

Investors should monitor three data points when results are announced: the revenue and PAT numbers relative to the estimates provided in this article, any formal FY27 guidance, and the dividend recommendation from the board. For real-time analysis and SEBI-registered expert views on Neuland Laboratories, visit 

Neuland Laboratories Q4 Results 2026 Date

Get free investment predictions and live Q4 result alerts on Univest.

Neuland Laboratories has scheduled its Q4 FY26 results for May 12, 2026. The board of directors will convene to approve audited financial statements for the quarter and full year ended March 31, 2026, and consider a final dividend recommendation.

Why This Quarter Matters

Q4 FY26 is the final quarter of the financial year — it determines full-year FY26 performance, establishes FY27 estimate baselines, and triggers final dividend announcements. For Neuland Laboratories, Q4 matters because the stock has delivered a -32% return over the past year, making the Q4 growth trajectory and management guidance crucial for sentiment recovery.

Institutional investors typically rebalance portfolios at the end of March, and Q4 results provide the data clarity needed for positioning into the new financial year. Analyst targets — ranging from Rs 14,200 to Rs 14,500 — will be updated post-results based on actual Q4 performance and FY27 guidance.

Neuland Laboratories Q4 FY26 Earnings Estimates

Access premium SEBI-registered research on Univest.

Analysts from MOFSL, YES Securities, JM Financial, and ICICI Direct have published Q4 FY26 preview estimates for Neuland Laboratories. Consensus revenue stands at Rs 510–540 Cr, compared to Rs 440 Cr in Q3 FY26. PAT is estimated at Rs 72–90 Cr, with margin of EBITDA 20–23%.

Beyond the headline numbers, investors should watch FY27 revenue and margin guidance and the dividend declaration, as these will carry more weight for the stock’s re-rating than Q4 numbers alone.

Screen Neuland Laboratories fundamentals on the Univest Screener.

5 Key Factors That Will Drive Neuland Laboratories Q4 FY26 Performance

Pharma Sector Demand in Q4 FY26

Neuland Laboratories operates in the Pharma sector. Q4 FY26 has seen demand supported by year-end government spending, improving consumer activity, and global trade recovery. The company’s established market position enables it to capture incremental demand. Analysts project 15–22% YoY revenue growth for Q4 FY26, driven by volume improvement and pricing stability.

Operating Leverage and Margin Expansion

Higher volumes in Q4 FY26 enable improved fixed cost absorption at Neuland Laboratories’s operations. The EBITDA margin is expected to expand toward EBITDA 20–23%, up from EBITDA 21.6% in Q3 FY26. This improvement is driven by a combination of better product mix, cost efficiencies, and operational scale benefits. PAT growth from Rs 41 Cr in Q3 to Rs 72–90 Cr in Q4 reflects this operating leverage.

Management Execution on FY26 Annual Targets

Q4 FY26 is the final quarter of the financial year, and Neuland Laboratories’s management will be working to deliver on the full-year FY26 commitments made at the start of the year. Strong Q4 execution would validate management credibility and set a positive base for FY27 guidance. Any formal FY27 outlook will be closely tracked by analysts and institutional investors.

Capital Allocation and Dividend Policy

The board of Neuland Laboratories is expected to consider Rs 20–30 per share as a final dividend at the Q4 FY26 results board meeting. The quantum of the dividend signals management’s confidence in the company’s free cash flow generation and capital allocation discipline. A higher-than-expected dividend would be a positive catalyst for investor sentiment.

FY27 Guidance as Primary Re-Rating Catalyst

Beyond Q4 FY26 results, the management’s FY27 guidance — for revenue growth, margin outlook, and capital expenditure — will be the most market-moving element of the results announcement. Analyst price targets for Neuland Laboratories range from Rs 14,200 to Rs 14,500, and these will be revised post-results based on the guidance delivered.

5 Risks to Watch in Neuland Laboratories Q4 FY26

Revenue Miss Risk vs Q4 Estimates

If Neuland Laboratories’s Q4 FY26 revenue falls below the Rs 510–540 Cr estimate — due to execution delays, demand softness, or order cancellations — the stock could correct sharply. Revenue delivery versus estimates is the first watchpoint on results day. Even a small miss can trigger outsized selling in the current high-uncertainty macro environment.

Margin Compression from Cost or Pricing Pressure

Input cost increases, competitive pricing pressure, or adverse product mix in Q4 FY26 could compress Neuland Laboratories’s margins below the EBITDA 20–23% estimate. A margin miss combined with revenue shortfall would be the worst-case outcome for near-term stock performance, potentially pushing the stock below the 52-week low of Rs 9,800.

FII Selling and Macro Headwinds

The 26% US reciprocal tariff on Indian goods announced in April 2026 has triggered FII selling in Indian equities, creating a macro overhang. For Neuland Laboratories, indirect impacts include valuation multiple compression and reduced institutional demand for mid-cap and small-cap stocks regardless of company-specific fundamentals.

FY27 Guidance Disappointment

In the current market environment, forward guidance carries significantly more weight than the reported quarter. If management’s FY27 revenue or margin guidance at the Q4 results call falls below Street expectations, Neuland Laboratories’s stock could underperform even if Q4 numbers are in line with estimates.

Sector-Specific Regulatory and Policy Risk

The Pharma sector faces an evolving regulatory landscape. Policy changes — including environmental regulations, tax changes, or sector-specific compliance requirements — that increase costs or alter competitive dynamics could affect Neuland Laboratories’s profitability in ways not currently modelled in analyst consensus estimates.

Neuland Laboratories Share Price and Analyst Ratings

Neuland Laboratories is trading at Rs 11,200 as of early April 2026, against a 52-week high of Rs 18,500 and 52-week low of Rs 9,800. The 1-year return of -32% reflects sector headwinds. Market capitalisation stands at Rs 12,300 Cr.

Download the Univest iOS App or Univest Android App to track Neuland Laboratories’s live price and receive SEBI-backed research alerts.

Conclusion

Neuland Laboratories enters Q4 FY26 with Pharma sector tailwinds and management focused on delivering full-year FY26 targets. Revenue of Rs 510–540 Cr and PAT of Rs 72–90 Cr represent the analyst consensus expectation. The predominantly bullish analyst view — with targets ranging from Rs 14,200 to Rs 14,500 — suggests meaningful upside potential from the current price of Rs 11,200, contingent on Q4 results delivering to estimates and FY27 guidance being constructive. Investors should monitor Q4 revenue versus estimate, margin versus EBITDA 20–23% band, and FY27 guidance when results are announced on May 12, 2026.

This article is for informational and educational purposes only. Consult a SEBI-registered financial advisor before making investment decisions.

For more Q4 FY26 results previews, visit Univest Blogs.

Frequently Asked Questions

What is the Neuland Laboratories Q4 results 2026 date?

The Neuland Laboratories Q4 FY26 results date is May 12, 2026. The board will meet to approve audited Q4 FY26 financials and consider a dividend recommendation.

What is the Neuland Laboratories Q4 FY26 PAT estimate?

Analysts estimate Neuland Laboratories Q4 FY26 PAT at Rs 72–90 Cr, based on revenue of Rs 510–540 Cr and margin of EBITDA 20–23%.

What is Neuland Laboratories’s share price ahead of Q4 results?

Neuland Laboratories is trading at Rs 11,200. The 52-week high is Rs 18,500 and low is Rs 9,800. 1-year return is -32% and market cap is Rs 12,300 Cr.

Will Neuland Laboratories declare a dividend in Q4 2026?

Neuland Laboratories is expected to consider Rs 20–30 per share as a final dividend. The actual declaration will depend on Q4 FY26 profitability and the board’s capital allocation policy.

Which analysts have a Buy rating on Neuland Laboratories?

MOFSL (Target: Rs 14,500), YES Securities (Target: Rs 14,000), JM Financial (Target: Rs 13,500), ICICI Direct (Target: Rs 14,200) have positive ratings on Neuland Laboratories heading into Q4 FY26 results.

What were Neuland Laboratories Q3 FY26 results?

Neuland Laboratories reported revenue of Rs 440 Cr and PAT of Rs 41 Cr in Q3 FY26, with margin at EBITDA 21.6%. These form the base for Q4 FY26 consensus estimates.

When do Infosys and TCS announce Q4 results 2026?

TCS announced Q4 FY26 results on April 9, 2026. Read the TCS Q4 Results 2026 preview. Infosys announced Q4 FY26 results on April 23, 2026. Read the Infosys Q4 Results 2026 preview.

Is Neuland Laboratories a good investment ahead of Q4 results?

This depends on your risk appetite and portfolio context. Use the  to assess Neuland Laboratories fundamentals, and consult a SEBI-registered financial advisor before making investment decisions.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information including NSE/BSE filings and company investor relations pages. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.

Recent Article

Motisons Jewellers Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Motilal Oswal Financial Services Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Moschip Technologies Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Morepen Laboratories Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Morarjee Textiles Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook